HER2 inhibition: From discovery to clinical practice

被引：41

作者：

Chang, Jenny C. ^{[1
]}

机构：

[1] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 01期

关键词：

D O I：

10.1158/1078-0432.CCR-06-2405

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 3

页数：3

共 35 条

[1] Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J].

Amundadottir, LT ;

Leder, P .

ONCOGENE, 1998, 16 (06) :737-746

[2] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[3]

Blackwell KL, 2004, J CLIN ONCOL, V22, p196S

[4] Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen [J].

Buzdar, Aman U. ;

Valero, Vicente ;

Ibrahim, Nuhad K. ;

Francis, Deborah ;

Broglio, Kristine R. ;

Theriault, Richard L. ;

Pusztai, Lajos ;

Green, Marjorie C. ;

Singletary, Sonja E. ;

Hunt, Kelly K. ;

Sahin, Aysegul A. ;

Esteva, Francisco ;

Symmans, William F. ;

Ewer, Michael S. ;

Buchholz, Thomas A. ;

Hortobagyi, Gabriel N. .

CLINICAL CANCER RESEARCH, 2007, 13 (01) :228-233

[5] Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [J].

Chang, JC ;

Wooten, EC ;

Tsimelzon, A ;

Hilsenbeck, SG ;

Gutierrez, MC ;

Elledge, R ;

Mohsin, S ;

Osborne, CK ;

Chamness, GC ;

Allred, DC ;

O'Connell, P .

LANCET, 2003, 362 (9381) :362-369

[6] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].

Cho, HS ;

Mason, K ;

Ramyar, KX ;

Stanley, AM ;

Gabelli, SB ;

Denney, DW ;

Leahy, DJ .

NATURE, 2003, 421 (6924) :756-760

[7]

DEES EC, 2004, P AN M AM SOC CLIN, V22, P3188

[8]

DESIMONE PA, 2002, 38 ANN M AM J CLIN O, V21, pA94

[9] C-ERBB-2 PROTEIN OVEREXPRESSION IN BREAST-CANCER IS A RISK FACTOR IN PATIENTS WITH INVOLVED AND UNINVOLVED LYMPH-NODES [J].

GULLICK, WJ ;

LOVE, SB ;

WRIGHT, C ;

BARNES, DM ;

GUSTERSON, B ;

HARRIS, AL ;

ALTMAN, DG .

BRITISH JOURNAL OF CANCER, 1991, 63 (03) :434-438

[10] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

← 1 2 3 4 →